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Hes1 is a direct Notch1 target; however, its precise function is unclear. In this issue of Immunity, Wendorff
et al. (2010) report that Hes1 regulates the number of T cell progenitors and has important functions in
both the induction and maintenance of T cell leukemia.Hairy and Enhancer of Split 1 (Hes1) is an
evolutionarily conserved direct Notch
transcriptional target whose expression
is frequently used as a surrogate for
Notch signaling. Hes1 is a transcriptional
repressor that is a member of the basic
helix-loop-helix (bHLH) family of tran-
scription factors and contains domains
that mediate DNA binding, dimerization,
and transcriptional repression (Kageyama
et al., 2007). Hes mediates repression by
directly binding DNA and inhibiting gene
expression or dimerizing with bHLH tran-
scriptional activators to inhibit their DNA
binding and activity. There are seven
mammalian Hes family members, but
only Hes1, Hes5, and Hes7 are direct
Notch targets. Although Hes1 is a Notch
transcriptional target, this relationship is
not exclusive; Hes1 can be transcribed
independently of Notch via other tran-
scription factors that include E47, JunB,
and the Hedgehog target Gli1.
In hematopoiesis, Notch is required to
establish embryonic hematopoietic stem
cells (HSCs) and to specify the T cell and
marginal zone B (MZB) cell lineages
(Radtke et al., 2010). Although the tran-
scriptional targets of Notch in embryonic
HSCs are poorly understood, Hes1 and
Hes5 are both expressed in developing
T and MZB cells. Hes1 is also a tran-
scriptional target of oncogenic Notch1
signaling that is associated with T cell
acute lymphoblastic leukemia (T-ALL).
The precise functions of Hes1 in these
Notch-dependent processes are poorly
understood.
Previouswork has provided some clues
to the potential function of Hes1 in these
processes (Radtke et al., 2010). Gain-of-
function studies in murine and human
HSCs suggested that Hes1 may promote
HSC self-renewal and/or quiescence;
however, HSC defects were not reportedin Hes1-deficient mice. In contrast, T cell
defects were described in Hes1-deficient
mice. Hes1-deficient mice die during
gestation or perinatally because of severe
neural tube defects. Analysis of T cell
development by means of fetal liver
chimeras or fetal thymic organ culture
suggested that Hes1 had important func-
tions in both T cell fate specification and
ab T cell development (Kaneta et al.,
2000; Tomita et al., 1999).
In order to better define the requirement
for Hes1 signaling in the hematopoietic
system and bypass the lethality of the
Hes1-deficient mice, Wendorff et al.
(2010) generated mice that contained
a floxed Hes1 allele capable of conditional
deletion. To test the function of Hes1 in
adult HSCs, they crossed floxed Hes1
mice with Mx-Cre mice and deleted Hes1
in bone marrow cells via interferon-a
(IFN-a) induction. No HSC defects were
observed in homeostatic or competitive
conditions, suggesting that similar to
Notch, Hes1 does not exert an essential
function in adult murine HSCs. MZB cell
development was also normal in these
mice. The absence of phenotypes in
these lineages was not due to incomplete
deletion or transcriptional upregulation
of Hes5.
Unlike HSCs andMZB cells, Hes1 dele-
tion via Mx-Cre led to T cell defects. There
was a marked decrease in total thymo-
cyte numbers beginning at the earliest
identifiable ETP (early thymic progenitor,
also known as DN1) T cell (CD117+
CD44+CD25); however, all downstream
progeny were present and conditional
deletion of Hes1 by CD4- or Lck-Cre did
not alter T cell differentiation. The effect
is cell autonomous and does not appear
to involve defective homing to the
thymus because delivery of Hes1-defi-
cient progenitors to the thymus via intra-Immunity 33, Nthymic injections gave similar results.
Thus, a critical function of Hes1 is opti-
mizing the number of T cells that arise
from a multipotent progenitor, a Notch1-
dependent function. Unlike Notch1- or
RBP-J-deficient mice, ablation of Hes1
did not result in an excess of thymic B
cells. Further evidence that Hes1 func-
tioned to tune the Notch signal came
from stromal cell cultures in which the
Hes1-deleted progenitors were exposed
to either OP9 cells expressing the delta-
like ligand, DLL4 (OP9-DLL4), which
provides strong signals to Notch1, or
OP9-DLL1, which provides weaker sig-
nals to Notch1. Plating Hes1-deficient
cells on OP9-DLL1 yielded fewer T cells
and greater numbers of B cells than either
Hes1-deleted cells on OP9-DLL4 stromal
cells or the wild-type controls.
These results, together with the
previous studies in Hes1-deficient mice,
provide strong evidence that Hes1 regu-
lates the ability of Notch1 signals to effi-
ciently generate T cells from multipotent
progenitors (Figure 1), thus raising the
question of the identity of the mechanism.
In directing cell fate decisions, Notch
delivers both inductive signals that pro-
mote the specific lineage as well as
repressive signals that inhibit alternative
cell fates. As a transcriptional repressor,
Hes may be required to efficiently repress
signals that promote non-T lineages. For
example, Hes1 overexpression inhibits
the transcription factor, C/EBPa, which
promotes myelopoiesis (Nakahara et al.,
2010). Although this hypothesis is alluring,
Wendorff et al. (2010) found no evidence
of skewing toward the B or myeloid line-
ages in the Hes1-deficient mice. Alterna-
tively, Hes may promote important sur-
vival or proliferation signals. Hes can
directly bind and repress expression of
the cyclin-dependent kinase inhibitorovember 24, 2010 ª2010 Elsevier Inc. 645
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Figure 1. Notch1 Requires Hes1 for Efficient T Cell Specification and Leukemic
Transformation
Notch1 signals induce T cell specification from a multipotent progenitor (MPP) in the thymus. In the
absence of Hes1, specification is impaired. Oncogenic Notch1 signals transform T cell progenitors to
induce T-ALL. In the absence of Hes1, oncogenic Notch signals are unable to induce T-ALL. In addition,
Notch-dependent T-ALL cells require persistent Hes1 signals to maintain growth and survival.
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Previewsp27KIP1 in HeLa cells, and Hes1-deficient
thymocytes exhibit increased p27KIP1
mRNA (Murata et al., 2005). As p27KIP1
inhibits proliferation, Hes1 absence might
decrease proliferation. AlthoughWendorff
et al. (2010) did not observe proliferative
or survival defects in the Hes1-deficient
thymocytes, it is possible that small
changes in the proliferation or survival of
the few ETP cells could account for the
much larger changes in cell numbers
observed in downstream progeny.
Wendorff et al. (2010) also investigated
the requirement of Hes1 in T-ALL. Acti-
vating Notch1 mutations are frequent
in human and mouse T-ALL and expres-
sion of activated Notch alleles in murine
HSCs and early T cell progenitors effi-
ciently induces T-ALL in mice (Aster et al.,
2010). Wendorff et al. (2010) asked
whether oncogenic Notch signaling in the
absence of Hes1 would induce T-ALL.
For these experiments, they crossed their
conditional Hes1-deficient mice with mice
that conditionally express an oncogenic
Notch1 allele (ICN1DPEST) from the
Rosa26 locus. Unlike control mice that
died from T-ALL with a median survival of
26 days, the median survival of the Hes1-
deficient mice was 250 days and none
showed obvious signs of T-ALL as mea-
sured by high numbers of immature
T cells in the peripheral blood, spleen, or
bone marrow. Although these data seem646 Immunity 33, November 24, 2010 ª2010to indicate that Hes1 is required to induce
T-ALL, it is possible that the decreased
numbers of T cell progenitors in the Hes1-
deficient mice has decreased the cell pop-
ulation at risk for acquiring the additional
genetic hits that synergize with Notch to
induce T-ALL. All of the Hes1-deficient
mice expressing ICN1 died at earlier times
than the control mice, so it will be inter-
esting to determine the cause of death in
order to rule out T cell lymphomas in other
organs as well as to provide insight into
morbidity caused by either other tumors
or nononcogenic events.
Although a role for Hes1 in leukemia
induction is interesting, the issue of
whether persistent Hes1 signals are
important for tumor maintenance is the
more important from a clinical vantage
because therapeutic interventions typi-
cally occur postdiagnosis. To address
this question, Wendorff et al. (2010) used
a retroviral bonemarrow transplant model
in which they transduced floxed Hes1
cells with an ICN1-expressing retrovirus,
injected these cells into recipients and
waited for T-ALL to occur, and then indu-
cibly deleted Hes1 via IFN-a induction.
Remarkably, the tumors rapidly shrunk,
suggesting that they were Hes1 depen-
dent. However, all tumors returned, even-
tually killing the mice. Importantly, the
relapsed tumors retained the floxed
Hes1 allele, suggesting that the smallElsevier Inc.subset of cells that retained Hes1 expres-
sion had a selective advantage that led to
tumor recurrence. T-ALL dependence on
Hes1 was not limited to murine models
as shown by the fact that Wendorff et al.
(2010) knocked down Hes1 in a human
Notch-dependent cell line and found
that these cells exhibited a growth disad-
vantage and died. Together, these data
strongly suggest that Notch1-induced
T-ALLs are Hes1 dependent (Figure 1).
Previous work showed that Notch-
induced T-ALLs require c-Myc and/or
Akt-PI3K signals; however, both seemed
to be intact in the Hes1-deleted, Rosa-
ICN1 double-positive T cells that tran-
siently appeared in thesemice. Thesecells
did not undergo leukemic transformation,
which suggests that Hes1 regulates addi-
tional targets that are involved in Notch-
dependent T-ALL. One potential candi-
date is the deubiquitinase CylD, which
is a direct Hes1 target in T-ALL and regu-
lates NF-kB transcription factor activity
by inhibiting IkB kinase (IKK) (Espinosa
et al., 2010). Normally, NF-kB is main-
tained in an inactive state through binding
to IkB. In the presence of IKK, IkB is
degraded and NF-kB is activated. In the
presence of oncogenic Notch signaling
and constitutive Hes1 expression, CylD
transcription is repressed, leading to IKK
and NF-kB activity and T-ALL cell growth.
In contrast, inhibition of NF-kB activity by
Hes1 suppression, CylD activation, or an
IKK inhibitory peptide inhibitors blocks
T-ALL growth (Espinosa et al., 2010). The
conditional Hes1 deletion model de-
scribed by Wendorff et al. (2010) provides
an excellent reagent to further test the role
of the Hes1:CylD axis in T-ALL. An addi-
tional role for Hes1 in leukemogenesis
may be due to its ability to regulate signals
that allow survival of quiescent cells, as
shown by the fact that inhibiting Hes1 in
quiescent fibroblasts or rhabomyosar-
coma cells induced either senescence
or differentiation, both of which could
contribute to attenuatingHes1-dependent
tumorgrowth (Sanget al., 2008). This latter
mechanism may be especially relevant to
Notch1-induced T-ALL if the Notch1
tumors are maintained by a small popula-
tion of tumor stem cells.
In summary, the work from Wendorff
et al., (2010) has identified an important
role for Hes1 in T cell specification and
revealed unanticipated roles for Hes1 in
tumor induction and maintenance.
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PreviewsFurther studies will determine whether
these disparate processes involve similar
mechanisms. Of clinical importance, the
dependence of Notch1-induced T-ALL
on persistent Hes1 signals provides the
impetus to further test Hes1 pathway
inhibitors, which may also be relevant to
tumors where Hes1 is activated indepen-
dently of Notch.
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The mechanisms that direct cell-type-specific peroxisome proliferator-activated receptor (PPAR) gene
programs are poorly understood. In this issue of Immunity, Szanto et al. (2010) identify signal transducer
and activator of transcription 6 as a transcriptional switch that licenses PPARg-dependent gene expression
in macrophages and dendritic cells.Macrophages are central components of
the innate immune system that are critical
for host defense. Found in almost all
tissues, they exhibit wide heterogeneity
and acquire a variety of functional pheno-
types depending on the external milieu.
For example, dendritic cells and macro-
phages present foreign antigens and
coordinate inflammatory responses trig-
gered by microbial pathogens through
the production of proinflammatory
factors. In other contexts, they clear
apoptotic cells and facilitate tissue re-
modeling and resolution of inflammation
through production of anti-inflammatory
mediators. Classical activation of macro-
phages (M1 phenotype) is induced by T
helper 1 (Th1) cell inflammatory cytokines
such as tumor necrosis factor a (TNFa)
and interferon-g (IFNg) and by pathogen
activation of Toll-like receptors (TLRs).
M1 activation leads to a coordinated
inflammatory response that primes cells
to deal with pathogens. Alternative activa-
tion of macrophages (M2 phenotype) canbe triggered by Th2 cell-activated T cells,
mast cells, basophils, eosinophils, or
macrophages through release of the cyto-
kines interleukin (IL)-4 or IL-13. Alternative
activation has been implicated in parasitic
infections, allergy, tissue repair, and in-
flammation. Although it is useful to lump
macrophages into the M1 and M2 cate-
gories for the purposes of broad discus-
sion, it is likely that a continuum of pheno-
types between these rigid categories is
adopted by endogenous macrophages,
depending on the cellular context.
In this issue of Immunity, Szanto et al.
(2010) elucidate a mechanism whereby
alternative macrophage activation leads
to enhanced peroxisome proliferator-acti-
vated receptor g (PPARg)-dependent
gene expression. PPARg is a ligand-acti-
vated transcription factor that was origi-
nally characterized as a master regulator
of adipogenesis. PPARs form obligate
heterodimers with retinoid X receptors
(RXRs) that bind to cis-regulatory
elements (PPREs) found in proximalpromoters, introns, or distal regions of
their target genes. In adipose cells,
PPARg regulates the expression of genes
involved in differentiation, lipid uptake,
and triglyceride storage. PPARg is also
the target of a popular class of antidia-
betic drugs, thiazolidinediones, that act
as direct ligands of the receptor.
In addition to adipose tissue, PPARg is
highly expressed in macrophages and is
induced during monocyte differentiation
and dendritic cell maturation. It has been
recognized for several years that the gene
expression programs induced by PPARg
ligands in adipocytes and macrophages
are only partially overlapping, raising the
question of how cell-type specificity is
accomplished. Lazar and colleagues
have recently reported that binding sites
for the transcription factor PU.1 are
present, together with PPREs, in many
macrophage-expressed PPARg target
genes (Lefterova et al., 2010). This charac-
teristic distinguishes them fromadipocyte-
selective target genes, which commonlyovember 24, 2010 ª2010 Elsevier Inc. 647
